Why Is Arcturus Therapeutics Stock Gaining Thursday?
Arcturus Therapeutics (ARCT) surged over 6% after sharing positive Phase 2 interim data for its OTC deficiency drug, ARCT-810.
Stocks · News reference
Arcturus Therapeutics Announces Interim Phase 2 Results From ARCT-810 In OTC Deficienc And Introduces LUNAR 2.0
ARCT-810 generally safe and well tolerated, demonstrating encouraging activity across key urea cycle biomarkers in ongoing Phase 2 studyLUNAR 2.0™ produces greater than 30-fold higher protein expression in multiple NHP
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Citigroup Upgrades Arcturus Therapeutics to Buy, Raises Price Target to $20
Citigroup analyst Yigal Nochomovitz upgrades Arcturus Therapeutics (NASDAQ:ARCT) from Neutral to Buy and raises the price target from $8 to $20.
Everpure, Fervo Energy, Charles River Laboratories And Other Big Stocks Moving Higher On Thursday
Nasdaq fell 150+ points, while Everpure jumped 14% after unveiling growth plans and a FY2028 outlook; other stocks also gained.
BTIG Maintains Buy on Arcturus Therapeutics, Lowers Price Target to $20
BTIG analyst Thomas Shrader maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Buy and lowers the price target from $23 to $20.